Analyst Ratings for [ALKS] Alkermes plc

7/15/25	Initiated	Buy	X
ALKS Alkermes Plc Goldman
$43
6/17/25	Upgrades	Neutral Buy	X
ALKS Alkermes Plc UBS
$42
5/28/25	Initiated	Buy	X
ALKS Alkermes Plc Needham
$45
3/13/25	Initiated	Sector Perform	X
ALKS Alkermes Plc RBC Capital Mkts
$40
3/4/25	Upgrades	Sell Neutral	X
ALKS Alkermes Plc UBS
$21 $38
2/11/25	Initiated	Buy	X
ALKS Alkermes Plc Deutsche Bank
$40
11/5/24	Upgrades	Hold Buy	X
ALKS Alkermes Plc Stifel
$25 $36
3/19/24	Initiated	Outperform	X
ALKS Alkermes Plc Robert W. Baird
$37
2/20/24	Downgrades	Neutral Sell	X
ALKS Alkermes Plc UBS
$25
11/20/23	Resumed	Neutral	X
ALKS Alkermes Plc JP Morgan
$33
10/24/23	Upgrades	In-line Outperform	X
ALKS Alkermes Evercore ISI
11/3/22	Upgrades	Neutral Overweight	X
ALKS Alkermes Piper Sandler
$26 $30
10/14/22	Upgrades	Underperform Neutral	X
ALKS Alkermes BofA Securities
$27 $25
8/16/22	Initiated	Neutral	X
ALKS Alkermes Piper Sandler
$26
4/22/22	Resumed	Buy	X
ALKS Alkermes Goldman
$35
4/20/22	Initiated	Buy	X
ALKS Alkermes Goldman
$35
1/27/22	Upgrades	Hold Overweight	X
ALKS Alkermes Cantor Fitzgerald
$32
12/1/21	Initiated	Neutral	X
ALKS Alkermes Citigroup
$22
10/7/21	Upgrades	Hold Buy	X
ALKS Alkermes Jefferies
$36
7/15/19	Upgrades	Sell Neutral	X
ALKS Alkermes Goldman
5/31/19	Initiated	Neutral	X
ALKS Alkermes H.C. Wainwright
5/1/19	Downgrades	Buy Neutral	X
ALKS Alkermes Citigroup
12/19/18	Downgrades	Neutral Sell	X
ALKS Alkermes Goldman
12/14/18	Initiated	Underperform	X
ALKS Alkermes Wolfe Research
12/13/18	Downgrades	Outperform Underperform	X
ALKS Alkermes Credit Suisse
11/5/18	Initiated	Neutral	X
ALKS Alkermes Piper Jaffray
$40
8/7/18	Initiated	Hold	X
ALKS Alkermes Stifel
$15 $45
6/21/18	Downgrades	Eq-Weight Underweight	X
ALKS Alkermes Morgan Stanley
6/6/18	Initiated	Buy	X
ALKS Alkermes B. Riley FBR, Inc.
$60
5/16/18	Upgrades	Neutral Buy	X
ALKS Alkermes Citigroup
5/11/18	Initiated	Buy	X
ALKS Alkermes BofA/Merrill
$56
2/22/18	Downgrades	Buy Hold	X
ALKS Alkermes Jefferies

ALKS Alkermes plc

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.